Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO® as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy

bluebird bio Appoints Joanne Smith-Farrell, Ph.D., to Chief Business Officer

Taris Bio Initiates New Clinical Study Of Tar-302 In Overactive Bladder

Magenta Therapeutics Announces Pricing of Public Offering

Jounce Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019